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1684-1182/Copyright ª 2014, TaiwanBackground/Purpose: Enterobacter cloacae is a well-recognized nosocomial pathogen. Use of
a rapid, in vivo infection model for E. cloacae that can determine the efficacy of antibiotic
therapies could help facilitate screening for new treatments. Nonmammalian model systems
of infection, such as Galleria mellonella, have significant logistical and ethical advantages
over mammalian models.
Materials and methods: We utilized G. mellonella larvae to determine the utility of this infec-
tion model to study antibacterial efficacy. G. mellonella killing with heat-killed or live clinical
isolates (E. cloacae GN1059 and GN0791) was tested. We also investigated the effect of post-
inoculation incubation temperature on the survival of infected larvae. The protection of
administration of antibiotics to infected larvae was investigated. Finally, we determined the
G. mellonella hemolymph burden of E. cloacae after administration of different antibiotics.
Results: With live bacterial inocula, G. mellonella killing was significantly dependent on the
number of E. cloacae cells injected in a dose-dependent manner. Further, we observed that
survival was reduced with increasing the postinoculation temperature. Treatment of a lethal
E. cloacae infection with antibiotics that had in vitro activity significantly prolonged the sur-
vival of larvae compared with treatment with antibiotics to which the bacteria were resistant.of Infectious Disease, the First Affiliated Hospital of Anhui Medical University, Jixi Road Number 218,
l.com (J.-B. Li).
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j.jmii.2014.11.011The therapeutic benefit arising from administration of antibiotic correlated with a reduced
burden of E. cloacae cells in the hemolymph.
Conclusion: The G. mellonella infection model has the potential to be used to facilitate the
in vivo study of hostepathogen interactions in E. cloacae and the efficacy of antibacterial
agents.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Enterobacter cloacae is a well-recognized nosocomial
pathogen that causes significant infections. It comprises
part of the normal flora of the gastrointestinal tract of
40e80% of the population and is widely distributed in the
environment.1,2 Like most members of the Enter-
obacteriaceae family, these microorganisms are important
nosocomial pathogens capable of causing opportunistic in-
fections among hospitalized or debilitated and immuno-
suppressed patients.3 E. cloacae is responsible for various
infections, including bacteremia, lower respiratory tract
infections, skin and soft-tissue infections, urinary tract in-
fections, and intra-abdominal infections. Clinical aware-
ness of the potential of E. cloacae strains to cause disease
has been reflected in the increasing number of epidemio-
logic studies of these microorganisms showing that they
could be a serious cause of nosocomial Gram-negative
bacteremia.4e6 The treatment of E. cloacae has become
difficult due to resistance to antibiotics. This microor-
ganism is intrinsically resistant to ampicillin and narrow-
spectrum cephalosporins, due to a chromosomal cepha-
losporinase. Additional resistance to broad-spectrum
cephalosporins and aztreonam is usually related to the
mutational overproduction of the species-specific cepha-
losporinase, or production of plasmid-mediated extended-
spectrum b-lactamases.7,8 Imipenem resistance has been
described in strains with porin alterations combined with
hyperproduction of chromosomal cephalosporinase, and in
strains producing class A carbapenem hydrolyzing non-
metallo-b-lactamases, such as NmcA and IMI-1.9e11
Due to the discrepancies between susceptibilities of
multidrug resistant E. cloacae in vitro and in vivo, data
determined in vivo are essential to reliably inform about the
true clinical potential of any novel antibiotic treatment.
Thus, use of a rapid, in vivo infection model for E. cloacae
that can determine the efficacy of antibiotic therapies could
help facilitate screening for new treatments. Typically, a
mammalian system is used, but these experiments are time-
consuming, expensive, and require full ethical consider-
ation.12,13 Hence, there is a need for preliminary and
alternative infection models that generate in vivo data
quickly and inexpensively and that do not require the same
ethical considerations. Invertebrate models have gained
increased attention as a viable alternative to mammalian
models.14e16 The introduction of a wax moth (Galleria
mellonella) model of systemic E. cloacae infection may
prove useful to this end. Larvae of the greater wax moth,
colloquially termed “wax worms” due to their naturalang H-F, et al., Galleria mellone
infection, Journal of Microbiologlifestyle of infesting beehives and consuming beeswax, have
already been used to determine the virulence of various
human pathogens, and to study therapeutics for infections,
including those caused by Gram-positive and Gram-negative
bacteria and several pathogenic fungi.17e22
Using a G. mellonella model has a number of advantages
over traditional mammalian models. First, the insects have
sophisticated cellular and humeral defenses, including the
production of antimicrobial peptides, which is similar to the
innate immune response of mammals. Hemocytes are the
major mediator of cellular defenses, which perform similar
functions to human macrophages and neutrophils. Second,
the larvae can be easily maintained and can be infected by
injection without anesthesia. Third, the larvae are not
subject to the ethical limitations of mammalian models.
Finally, and of great novelty, the G. mellonella model is
amenable for assessing the efficacy of antimicrobial agents,
and can be maintained at temperatures of 37C, which are
well suited to study human pathogens.20,21
The aim of this study was to evaluate the potential of G.
mellonella larvae as an in vivo infection model for E.
cloacae and to determine whether the efficacy of antimi-
crobial treatment can be assessed.
Materials and methods
Reagents, bacteria and insects
All reagents and culture media were purchased from Sigma-
Aldrich Ltd (St. Louis, MO, USA). All solutions were made
using sterile deionized water. Water, phosphate buffered
saline (PBS), and media were sterilized by autoclaving at
121C for 15 minutes. The clinical isolates of E. cloacae
used in this study are summarized in Table 1. Bacteria were
cultured overnight in Luria-Bertani broth aerobically at
37C with shaking, to prepare inocula for antibiotic sus-
ceptibility testing in vitro and antibiotic efficacy testing
in vivo. Batches of G. mellonella larvae (Kaide ruixin Co.,
Ltd, Tianjin, China) in their final instar stage were stored in
the dark at 4C and used within 7 days from shipment.
Larvae masses varied slightly, but were typically 250 mg,
and this value was used to calculate treatment doses.
Determination of minimum inhibitory
concentration
The minimum inhibitory concentrations (MICs) of piper-
acillin (PIP), cefotaxime (CTX), imipenem (IMP), amikacinlla as an in vivo model for assessing the efficacy of antimicrobial
y, Immunology and Infection (2014), http://dx.doi.org/10.1016/
Table 1 Minimum inhibitory concentrations (MICs) of an-
timicrobials against Enterobacter cloacae GN1059 and
GN0791
Antimicrobials MIC (mg/L)
GN1059 GN0791
PIP 32 256
CTX 0.25 512
IMP 0.5 64
AMK 2 256
CIP 1 16
AMK Z amikacin; CIP Z ciprofloxacin; CTX Z cefotaxime;
IMP Z imipenem; PIP Z piperacillin.
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and GN0791 were determined using the microtiter broth
dilution method. In brief, an inoculum of 5  105 colony-
forming units (cfu)/mL was used, and the test was con-
ducted in Luria-Bertani broth. Plates were incubated at
37C and the MIC was defined as the lowest concentration
of antibiotic where no bacterial growth was observed.
Strains were classified as resistant to certain antibiotics if
they grew in levels equal to or above the MIC breakpoint as
defined by the Clinical and Laboratory Standards Institute
(CLSI). Escherichia coli ATCC 25922 was used for the
quality control. Each experiment was performed in
triplicate.
G. mellonella killing with heat-killed or live E.
cloacae
Bacterial infection of G. mellonella was performed as
described previously,21 with minor modifications. Briefly,
bacterial cells were washed with PBS and then diluted to an
appropriate cell density. Bacterial colony counts on
Mueller-Hinton (MH) agar were used to confirm all inocula.
A 50-mL Hamilton syringe was used to inject 10 mL aliquots
of the inoculum into the hemocoel of each larva via the last
left proleg. After injection, larvae were incubated in Petri
dishes in the dark at 37C for 5 days. Unless stated, 15
randomly chosen larvae were used for each group of an
experiment and each experiment was repeated using larvae
from a different batch. For heat-killed inoculum experi-
ments, the bacterial suspension was heated in a water bath
at 100C for 10 minutes. Heat killing was confirmed to
contain no viable bacteria by plating them on MH agar and
incubating at 37C for 48 hours. The heat-killed bacterial
suspension was diluted with PBS and inocula containing
1  1061  108 cfu were used to infect groups of larvae, as
above. In all experiments, there were two negative control
groups; one group that underwent no injection, while the
other group was injected with PBS only, which controlled
for the impact of physical trauma.
Effect of postinoculation temperature on larval
survival
To investigate the effect of postinoculation incubation
temperature on the survival of infected larvae, larvae werePlease cite this article in press as: Yang H-F, et al., Galleria mellone
agents against Enterobacter cloacae infection, Journal of Microbiolog
j.jmii.2014.11.011inoculated with 5  105 cfu/larva of live bacteria and
incubated at 25C, 30C or 37C. Negative control groups
were set up for each incubation temperature.Administration of antibiotics
Groups of larvae were infected with a lethal inoculum of E.
cloacae GN1059 and GN0791 as above, and all larvae were
confirmed to be alive at 2 hours postinoculation. Then,
antibiotics were administered in PBS by injection into a
different proleg. Larvae injected twice with PBS were used
as the control group. The antibiotics and doses included PIP
(100 mg/kg), CTX (150 mg/kg), IMP (50 mg/kg), AMK
(15 mg/kg), and CIP (10 mg/kg). Doses were based on those
used for humans.Determination of G. mellonella hemolymph burden
of E. cloacae
Experiments were performed as described previously,23
except for minor modifications. In brief, groups of 30
larvae were infected with 5  105 cfu/larva of either strain
of E. cloacae. Two hours after infection, a single dose of
antibiotic was administered as above. Larvae were incu-
bated in Petri dishes at 37C. At 24-hour intervals, five
larvae were selected randomly from each treatment group
and tested for hemolymph burden. In some cases where all
larvae present had died, then five dead larvae were
selected. Selected larvae were surface disinfected by vor-
texing in ethanol. The ethanol was poured off and the
larvae were allowed to dry. Once dry, each larva was placed
into a separate Eppendorf tube containing 300 mL of sterile
PBS. A clean Argos pestle (Argos Technologies Inc., Elgin, IL,
USA) was washed in ethanol, flamed, and used to homog-
enize the larva and release the hemolymph. A further
300 mL of sterile PBS was then added to each tube and
vortexed. Larval homogenate (20 mL) was serially diluted in
180 mL of MHB in a 96-well microplate (Thermo Fisher
Scientific Co., Ltd, Shanghai, China). This process was
repeated for each of the five larvae sampled/treatment
group every 24 hours. The dilution series was plated on MH
agar plates and incubated at 37C for 24 hours. Colonies
were counted after 24 hours and data were expressed as
viable cfu/mL. Using this method, the detection limit was
100 cfu/mL of larval homogenate.Statistical analyses
For statistical testing, data from duplicate experiments
were pooled to give n Z 30. These pooled survival data
were plotted using the Kaplan-Meier method and differ-
ences in survival were calculated using the log-rank test,
with a p value 0.05 indicating statistical significance. In
all comparisons with the negative control, it was the un-
infected control (rather than the unmanipulated control)
that was used. All statistical analyses were performed using
GraphPad Prism, version 5.04 (GraphPad Software Inc., San
Diego, CA, USA).lla as an in vivo model for assessing the efficacy of antimicrobial
y, Immunology and Infection (2014), http://dx.doi.org/10.1016/
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G. mellonella larvae are highly sensitive to
infection by E. cloacae
To determine whether G. mellonella larvae was a suitable
model to study E. cloacae pathogenesis, we first defined its
infection characteristics. The effect of infection with
E. cloacae GN1059 and GN0791 on the survival of G. mello-
nella larvae is shown in Fig. 1. With live bacterial inocula,
killing was significantly dependent on the number of
E. cloacae cells injected in a dose-dependent manner during
96 hours of incubation (Fig. 1). One hundred percent of theG.
mellonella larvaewere killedwithin 48 hours of infectionwith
at least 1  106 cfu/larva, whereas very few G. mellonella
larvae were killed with 1  104 cfu/larva or less (p < 0.05)
(Fig. 1).With both strains, the heat-killed E. cloacae inoculum
(up to the maximum inoculation dose of 5  107 cfu) had no
significant effect on larval survival. Further, we observed that
postinoculation temperature affected larval survival after
injection of live E. cloacae. It was shown that survival is
reduced with increasing postinoculation temperature. There
were no deaths in each of the uninfected control groups
(incubated at 25C, 30C, and 37C) (Fig. 2).
Together, these data indicate that infection with live
bacteria is required to cause larval death. Given the above-
described killing characteristics, for further G. mellonella
experiments, we used inocula of 5  105 cfu/larva and
incubated the infected larvae at 37C.In vitro sensitivities of E. cloacae to antibiotics
correlate with the efficacy of the antibiotics in vivo
The MICs of PIP, CTX, IMP, AMK, and CIP against E. cloacae
GN1059 and GN0791 are shown in Table 1. Antibiotics at
the concentrations used as mentioned above had no effect
on larval survival compared with the PBS-treated controls
(p < 0.05) and were therefore deemed to be nontoxic at
these doses (data not shown). The effects of single doses
of antibiotics 2 hours postinfection with either E. cloacae
GN1059 or GN0791 (inoculum 5  105 cfu/mL) on the sur-
vival of G. mellonella larvae are shown in Fig. 3. Larvae
infected with the susceptible strain GN1059 showed that
all five antibiotics resulted in significantly greaterFigure 1. Effect of varying inoculum doses of live Enterobacter
mellonella larvae during incubation at 37C for 96 hours showing tha
dependent manner. Data from the 107 cfu of heat-killed bacterial in
significant effect on larval survival.
Please cite this article in press as: Yang H-F, et al., Galleria mellone
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j.jmii.2014.11.011percentage survival compared with those larvae treated
with PBS only (p < 0.05; Fig. 3). In contrast, when G.
mellonella larvae were infected with an Multidrug-resis-
tant (MDR) E. cloacae GN0791, these treatment regimens
conferred no therapeutic benefit. In conclusion, the effi-
cacy of the antibiotics in vivo closely correlated with the
measured in vitro sensitivities (Table 1).
Successful antibiotic therapy results in a parallel
reduction in the larval burden of E. cloacae
For the larvae infected with E. cloacae GN1059, significant
differences (p < 0.05) were observed in the number of
log10 cfu/mL recovered from the larvae treated with an-
tibiotics mentioned above and the untreated larvae group
(Fig. 4). In contrast, a majority of larvae infected with
E. cloacae GN0791 and treated with either a single dose
mentioned above or PBS were dead after 24 hours. In par-
allel, under both treatments the larval burden increased
significantly for the 96-hour duration of the experiment.
For example, treatment with 150 mg/kg CTX prevented
the rapid growth of GN1059 over 24 hours and resulted in a
significant reduction in the number of viable bacteria pre-
sent within the larvae over the entire 96-hour duration of
the experiment (Fig. 4). In contrast, a single dose of 150 mg/
kg CTX had no inhibitory effect, as there was rapid prolif-
eration of GN0791 within the larvae over a period of 24 hours
(Fig. 4) and the numbers of GN0791 recovered were similar
to those from infected larvae treated with PBS alone.
In summary, the therapeutic benefit arising from
administration of an antibiotic closely correlated with a
drastic reduction in the larval burden of bacteria.
Discussion
A number of studies have utilized G. mellonella larvae to
study the virulence of certain microbial pathogens and the
efficacy of antimicrobial therapies against Gram-negative
pathogens.17e23 For example, the efficacy of different
antibiotic regimens versus larvae infected with Acineto-
bacter baumannii reflected precisely the known resistance
patterns of the strains employed.21 Desbois and Coote24
reported that antibiotics are also effective in the larva
model for the treatment of infections caused by Gram-cloacae (A) GN1059 or (B) GN0791 on the survival of Galleria
t survival is reduced with increasing doses of bacteria in a dose-
oculum is also given, showing that heat-killed E. cloacae had no
lla as an in vivo model for assessing the efficacy of antimicrobial
y, Immunology and Infection (2014), http://dx.doi.org/10.1016/
Figure 2. Effect of postinoculation temperature on the survival of Galleria mellonella larvae after infection with 5  105 cfu/
larva of live Enterobacter cloacae (A) GN1059 or (B) GN0791 showing that survival is reduced with increasing postinoculation
temperature.
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assessing the in vivo efficacy of candidate anti-
staphylococcal agents before proceeding to mammalian
studies, which may reduce animal experimentation and
expense. However, there are no documented studies that
have investigated the suitability of G. mellonella larvae for
studying the virulence of E. cloacae and the efficacy of
antimicrobial therapies against E. cloacae.
To determine whether G. mellonella larvae were a
suitable model to study E. cloacae pathogenesis, we first
defined its infection characteristics. Killing was significantly
dependent on the number of E. cloacae cells injected.
Results revealed a positive correlation between the inoc-
ulum number of E. cloacae cells and the death rate of
larvae. These data suggest that infection with live bacterial
cells is required for E. cloacae pathogenesis in G. mello-
nella larvae. Similar findings were described previously for
other pathogens.21,23,24
An important benefit of G. mellonella over other inver-
tebrate hosts such as Caenorhabditis elegans is its ability to
be maintained at temperatures of 37C, which are well
suited to study human pathogens. We found that higher
postinoculation temperatures cause greater reductions in
larval survival. This is in line with the previous observa-
tion.21,24 These data suggest that either E. cloacae haveFigure 3. Effect of antibacterial treatment on survival of Galleri
or GN0791. Antibacterials that are active against E. cloacae can p
with a lethal dose of E. cloacae GN1059, piperacillin (PIP) (100 mg/
amikacin (AMK; 15 mg/kg), and ciprofloxacin (CIP; 10 mg/kg), to
survival of G. mellonella larvae [p < 0.05 for comparison with phos
G. mellonella larvae, the antibacterials mentioned above, to wh
compared with PBS treatment.
Please cite this article in press as: Yang H-F, et al., Galleria mellone
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larvae are more susceptible to infection at the higher
temperature.
In our study, two E. cloacae strains with contrasting
antimicrobial resistance profiles were used to discriminate
the effect of treatment with a range of antimicrobials on
larvae infected with these two strains. Our study showed
that the efficacies of the antimicrobials on infected larvae
closely correlate with the known drug susceptibilities of the
two strains in vitro. Treatment of a lethal E. cloacae
infection with antibiotics that had in vitro activity against
the infecting E. cloacae strain significantly prolonged the
rate of survival of G. mellonella. Determination of larval
burden postinfection showed that effective antimicrobial
therapy drastically reduced the number of bacteria
detected inside the larvae. However, it was not possible
from this to ascertain whether this was due to a bacteri-
cidal effect reducing the inoculum size, or to a bacterio-
static effect on the inoculum preventing subsequent
outgrowth in the hemocoel. Taken together, these findings
confirm that the G. mellonella model may prove useful for
evaluating the in vivo efficacy of new antimicrobial agents.
In conclusion, very little is known about the pathogenic
mechanisms of E. cloacae, and thus, the G. mellonella
infection model described herein serves as a useful tool fora mellonella larvae infected with Enterobacter cloacae GN1059
rolong the survival of G. mellonella larvae. (A) After infection
kg), cefotaxime (CTX; 150 mg/kg), imipenem (IMP; 50 mg/kg),
which the strain was susceptible, significantly prolonged the
phate buffered saline (PBS)]. (B) However, for GN0791 infected
ich the strain was resistant, caused no difference in killing
lla as an in vivo model for assessing the efficacy of antimicrobial
y, Immunology and Infection (2014), http://dx.doi.org/10.1016/
Figure 4. Effect of a single dose of piperacillin (PIP; 100 mg/kg), cefotaxime (CTX; 150 mg/kg), imipenem (IMP; 50 mg/kg),
amikacin (AMK; 15 mg/kg), and ciprofloxacin (CIP; 10 mg/kg), on larval burden of Enterobacter cloacae GN1059 or GN0791. Larvae
were infected with 5  105 cfu/mL of either strain. For the susceptible strain E. cloacae GN1059, a significant difference in larval
burden between groups treated with phosphate buffered saline (PBS) or each antibacterial (p < 0.05); for the Multidrug-resistant
(MDR) strain E. cloacae GN0791, no difference in larval burden between groups treated with PBS or each antibacterial.
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+ MODELfuture research. The model also has the potential to be
used to study novel compounds for in vivo activity against
E. cloacae without the logistical, ethical, and financial
barriers that exist with mammalian models.
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